Due to convincing results with improved survival after radio(chemo)therapy (R(C)T) [2], the PD-L1 inhibitor durvalumab is routinely applied for unresectable, stage III non-small cell lung cancer (NSCLC) after RCT as maintenance therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.